• From Molecules to Medicine: Dr. Prakash Narayan's Biotech Breakthroughs

  • Jan 9 2025
  • Length: 49 mins
  • Podcast

From Molecules to Medicine: Dr. Prakash Narayan's Biotech Breakthroughs

  • Summary

  • Dr. Prakash Narayan is a distinguished biotech executive with over 20 years of experience in leading IND- and BLA-enabling programs from concept through clinical trials for heart, lung, kidney, and liver indications. As a founding member of a startup biotech that became a publicly traded company, Dr. Narayan has demonstrated exceptional leadership skills and a proven track record in nonclinical and translational R&D, attracting approximately $30 million in non-dilutive funding as a Principal Investigator from various organizations including NIH, NSF, DoD, and BARDA

    00:00 Introduction to the Life Science Success Podcast
    00:37 Sponsor Message: D3 Digital Media Marketing
    01:10 Guest Introduction: Dr. Prakash Narayan
    01:51 Journey from Academia to Biotech Executive
    04:34 Growing a Startup into a Publicly Traded Company
    06:49 Drug Development Process: From Discovery to FDA Filings
    12:53 Challenges and Future of Cell-Based Therapies
    16:10 Predictive Analytics in Biomedical Science
    19:10 Adapting Approaches Across Disease Areas
    22:56 Precision Medicine in Clinical Trials
    24:40 Understanding Fatty Liver Disease
    25:00 Precision Medicine: A Tailored Approach
    25:25 Repurposing Drugs for Kidney Disease
    27:10 The Role of Biobanks and Electronic Health Records
    28:26 Non-Dilutive Funding: Pros and Cons
    32:56 Exploring Transcriptomics and Functionomics
    36:55 The Impact of Technology and AI in Medicine
    40:53 Inspiration and Concerns for the Future
    47:42 Final Thoughts and Advice for Entrepreneurs

    Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about From Molecules to Medicine: Dr. Prakash Narayan's Biotech Breakthroughs

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.